卡维地洛对冠心病患者血浆氧化修饰低密度脂蛋白的影响

目的 :观察临床应用卡维地洛能否降低冠心病患者血浆氧化修饰低密度脂蛋白 (Ox LDL)水平。方法 :选择确诊冠心病患者及年龄、性别相匹配的正常对照组各 30例。冠心病组卡维地洛平均用量为 (10± 2 .5 )mg/d ,共 4个月 ,于服药前、服药后2个月及 4个月 ,分别采集清晨空腹血 ,以检测Ox LDL ,丙二醛 (MDA)。结果 :冠心病组的Ox LDL、MDA水平显著高于对照组 ,在用药后 2及 4个月冠心病组Ox LDL较用药前有显著降低 (P <0 .0 5 ) ,MDA显示出类似的趋势 (P <0 .0 1)。结论 :卡维地洛具有抗氧化作用 ,可以降低冠心病患者血浆Ox LDL水平。     

国产血管内介入治疗导管的临床应用

目的：探讨国产导管在血管内介入治疗中的价值。方法：应用60条国产血管内介入治疗导管行脑血管造影17例、盆腔动脉造影及栓塞6例、肝动脉造影及栓塞37例。结果：所有血管造影及治疗均成功完成。结论：国产血管内介入治疗导管能够满足介入治疗的需要。     

提高抗恶性疟独特型单抗克隆出现频率的方法学探讨

用Protein A-Sepharose亲和层析法提纯McAb-IgG,皮下多点和腹腔免疫雄性Wistar大鼠,间隔两周共3次,融合前3天采用腹腔、尾静脉和脾内注射等三种加强免疫方法,以间接ELISA法和抗体竞争ELISA法筛选Anti-Id阳性克隆。结果显示:融合前大鼠血清抗小鼠IgG或抗免疫原McAb-IgG滴度,静脉组和脾内组比腹腔组高一个滴度;Anti-Id阳性克隆出现频率,腹腔组为0.9％和0.3％,静脉组为11.0％和13.3％,脾内组为16.4％和12.9％,静脉组和脾内组明显高于腹腔组(P<0.01);上述三种加强免疫方法对抗小鼠IgG阳性克隆出现频率无明显影响(P>0.05);与腹腔加强免疫组相比,静脉和脾内加强免疫组也可提高细胞融合效果(P<0.01).本实验结果提示,腹腔和皮下多点多次长程基础免疫结合静脉或脾内加强免疫是制备Anti-Id McAb比较好的免疫方案。     

The epidemiology and surveillance of blood lead in Taiwan (R.O.C.): A report on the PRESS-BLL project

 To monitor the lead hazards in industries and to investigate the prevalence of elevated blood lead levels (BLLs) in lead-exposed workers, a lead surveillance system (PRESS-BLLs) has been established and operated in Taiwan, Republic of China, since July 1993. A cohort of lead-exposed workers who received a periodic annual health examination at 55 accredited hospital laboratories was constructed. A total of 9807 separate BLL measurements were reported to the system in 1994. The mean BLL was 15.8 μg/dl in male workers and 11.6 μg/dl in female workers. The mean BLL of lead-exposed workers was significantly (P<0.05, z-test) higher than that of the general Taiwanese population (8.6 μg/dl for males and 6.7 μg/dl for females). In addition, the BLLs of 983 (10.0%) workers exceeded the regulatory action level (40 μg/dl for males; 30 μg/dl for females). The workplaces and homes of 57% of the workers with elevated BLLs were thoroughly investigated to determine the sources of lead contamination. These actions identified the causes of elevated BLLs and set up strategies to reduce workers’ lead exposure. The establishment of this occupational lead surveillance system represents a method for monitoring of lead hazards from occupational and environmental settings to prevent lead poisoning. The information acquired from the system can help in the setting up of a priority of prevention and the development of control measures. It is also useful for further monitoring of changes in the BLLs of the lead-exposed-worker cohort. The Health Department of Taiwan can use this information to evaluate the effectiveness of current industrial hygiene practice. Subjects with elevated BLLs have been medically treated and placed on long-term follow-up for sequelae. Received: 2 September 1996/Accepted: 29 November 1996     

血管内氧合器的研制

为了探索呼吸辅助的新方法，我们采用国产聚丙烯中空纤维，自行设计、制造模具，研制出一种血管内氧合器。该氧合器是一个小的、细长的可经单侧股静脉或颈静脉切开，置入腔静脉内的装置。氧合器有效长度４０ｃｍ，膜交换面积０．０９ｍ＾２。经负压调节通过血管内氧合器的氧流量，以防止纤维破裂造成的血管内气栓的危险。一根双腔导气管使气体经同一静脉切开部位循环，气体经内芯管流经血管内氧合器尖端，然后经中空纤维束流出。目前     

心衰患儿红细胞内外钙离子浓度的变化及临床意义 心衰患儿红细胞内外钙离子浓度的变化及临床意义

目的：为了深讨心肌细胞内钙离子浓度的变化与心力衰竭发生的关系。方法：原子吸收分光技术测定红细胞内外Ca2+含量。我们对住院的56例心力衰竭患儿进行了红细胞内及血浆钙离子浓度的测定，并与30例正常小儿对照。结果：心衰患儿红细胞内Ca2+浓度明显升高，血浆Ca2+浓度降低，与对照组相比有非常显著性差异（P＜0．001）。其升高程度与心衰呈正相关（r=0．63，P＜0．01），即心衰越重，心功能越差，红细胞内Ca2+浓度升高亦越明显。而当心衰纠正，心功能恢复后，红细胞内Ca2+浓度则明显下降，血浆Ca2+浓度也恢复正常。而不同病因所致的心衰，其间红细胞内Ca2+浓度升高程度无明显差异。结论：提示钙离子参与了心力衰竭的发生与发展。     

牛磺酸对实验性高血压大鼠脑脊液和血浆内皮素含量的影响

目的探讨牛磺酸对实验性高血压大鼠脑脊液、血浆内皮素-1(ET-1)含量的影响.方法Wistar大鼠36只,随机分为高血压组,牛磺酸组和对照组3组,高血压组和牛磺酸组建立大鼠主动脉狭窄-高盐摄入性高血压模型,牛磺酸组饲料中加牛磺酸,观察3组大鼠脑脊液、血浆ET-1含量及血压的变化,测定脑组织和主动脉组织牛磺酸含量及主动脉肌条的舒缩功能.结果应用牛磺酸后,高血压大鼠pMA,脑脊液和血浆ET-1水平均下降(P<0.05),血管舒缩功能得以改善.结论牛磺酸可降低脑脊液、血浆ET-1水平,从而降低血压.     

应用结膜后退法矫治睑球粘连

目的：为眼部热力及化学性烧伤导致的睑球粘连寻找一种新的治疗方法。方法：用残留的结膜行1次或多次后退重建结膜囊。结果：1998年以来用此法为38例（40只眼）睑球粘连者进行了治疗，其中13例（13只眼）行2次，19例（21只眼）行3次，仅6例（6只眼）行1次结膜后退成功，其中1例失败。结论：结膜后退法是矫治睑球粘连的一些种有效的方法。     

A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy.

Selective removal of malignant cells (purging) from bone marrow (BM) is a concern in autologous BM transplantation (ABMT). Use of vincristine, etoposide, or doxorubicin for purging could be rendered ineffective by the presence of multidrug-resistant (MDR) tumor cells. To circumvent this particular problem, we investigated whether 17F9, a monoclonal IgG2b antibody directed against the cell surface product of the MDR gene, P-glycoprotein, is effective in selective removal of MDR cells from BM when used with rabbit complement (C'). Using two different cell lines we have demonstrated that 17F9 + C' selectively lyses MDR-positive cells. Three rounds of antibody + C' resulted in 96.4% +/- 3.6% kill of K562/DOX and 100% +/- 0% of CEM/VLB cells. Mixtures of malignant cells and normal BM resulted in 99.85% removal of K562/DOX and 99.91% removal of CEM/VLB clonogenic cells. This treatment did not affect normal committed precursors compared with C' alone. The addition of the cytotoxic agent etoposide (VP-16) following antibody purging results in a 4.6 log reduction of malignant cells. Furthermore, this antibody was effective when used against patients' leukemic blasts. These results suggest the use of 17F9 + C' is effective and selective for removal of MDR cells from BM before ABMT and the addition of VP-16 enhances the purging efficacy.